2022-RA-905-ESGO Mismatch repair deficiency is not applicable as biomarker in cervical cancer, yet MSH-2 has strong prognostic value | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Cervical cancer

2022-RA-905-ESGO Mismatch repair deficiency is not applicable as biomarker in cervical cancer, yet MSH-2 has strong prognostic value

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: van den Berg MC, Berg HF, Stokowy T, et al

2022-RA-905-ESGO Mismatch repair deficiency is not applicable as biomarker in cervical cancer, yet MSH-2 has strong prognostic value

International Journal of Gynecologic Cancer 2022;32:A32.